Switzerland · Delayed Price · Currency is CHF Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of CHF 251.34 billion. The enterprise value is 284.52 billion.
| Market Cap | 251.34B |
| Enterprise Value | 284.52B |
Important Dates
The last earnings date was Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | Mar 10, 2026 |
Share Statistics
Novartis AG has 1.89 billion shares outstanding. The number of shares has decreased by -2.76% in one year.
| Current Share Class | 1.89B |
| Shares Outstanding | 1.89B |
| Shares Change (YoY) | -2.76% |
| Shares Change (QoQ) | -0.47% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 43.80% |
| Float | 1.84B |
Valuation Ratios
The trailing PE ratio is 30.48 and the forward PE ratio is 16.60. Novartis AG's PEG ratio is 1.98.
| PE Ratio | 30.48 |
| Forward PE | 16.60 |
| PS Ratio | 5.25 |
| PB Ratio | 8.02 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.24 |
| P/OCF Ratio | 17.39 |
| PEG Ratio | 1.98 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.00, with an EV/FCF ratio of 21.78.
| EV / Earnings | 34.00 |
| EV / Sales | 5.94 |
| EV / EBITDA | 14.00 |
| EV / EBIT | 17.50 |
| EV / FCF | 21.78 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 1.29.
| Current Ratio | 0.88 |
| Quick Ratio | 0.58 |
| Debt / Equity | 1.29 |
| Debt / EBITDA | 1.98 |
| Debt / FCF | 3.09 |
| Interest Coverage | 12.36 |
Financial Efficiency
Return on equity (ROE) is 24.33% and return on invested capital (ROIC) is 19.26%.
| Return on Equity (ROE) | 24.33% |
| Return on Assets (ROA) | 10.86% |
| Return on Invested Capital (ROIC) | 19.26% |
| Return on Capital Employed (ROCE) | 23.04% |
| Weighted Average Cost of Capital (WACC) | 6.19% |
| Revenue Per Employee | 635,884 |
| Profits Per Employee | 111,194 |
| Employee Count | 75,267 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, Novartis AG has paid 2.19 billion in taxes.
| Income Tax | 2.19B |
| Effective Tax Rate | 20.80% |
Stock Price Statistics
The stock price has increased by +31.01% in the last 52 weeks. The beta is 0.46, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +31.01% |
| 50-Day Moving Average | 122.64 |
| 200-Day Moving Average | 121.88 |
| Relative Strength Index (RSI) | 65.81 |
| Average Volume (20 Days) | 3,672,215 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novartis AG had revenue of CHF 47.86 billion and earned 8.37 billion in profits. Earnings per share was 4.37.
| Revenue | 47.86B |
| Gross Profit | 36.00B |
| Operating Income | 16.26B |
| Pretax Income | 10.55B |
| Net Income | 8.37B |
| EBITDA | 20.08B |
| EBIT | 16.26B |
| Earnings Per Share (EPS) | 4.37 |
Balance Sheet
The company has 7.40 billion in cash and 40.31 billion in debt, with a net cash position of -32.90 billion or -17.42 per share.
| Cash & Cash Equivalents | 7.40B |
| Total Debt | 40.31B |
| Net Cash | -32.90B |
| Net Cash Per Share | -17.42 |
| Equity (Book Value) | 31.34B |
| Book Value Per Share | 16.45 |
| Working Capital | -3.15B |
Cash Flow
In the last 12 months, operating cash flow was 14.45 billion and capital expenditures -1.39 billion, giving a free cash flow of 13.06 billion.
| Operating Cash Flow | 14.45B |
| Capital Expenditures | -1.39B |
| Depreciation & Amortization | 3.75B |
| Net Borrowing | 13.26B |
| Free Cash Flow | 13.06B |
| FCF Per Share | 6.92 |
Margins
Gross margin is 75.21%, with operating and profit margins of 33.98% and 17.49%.
| Gross Margin | 75.21% |
| Operating Margin | 33.98% |
| Pretax Margin | 22.04% |
| Profit Margin | 17.49% |
| EBITDA Margin | 41.95% |
| EBIT Margin | 33.98% |
| FCF Margin | 27.80% |
Dividends & Yields
This stock pays an annual dividend of 3.70, which amounts to a dividend yield of 2.78%.
| Dividend Per Share | 3.70 |
| Dividend Yield | 2.78% |
| Dividend Growth (YoY) | 5.71% |
| Years of Dividend Growth | 28 |
| Payout Ratio | 90.40% |
| FCF Payout Ratio | 53.49% |
| Buyback Yield | 2.76% |
| Shareholder Yield | 5.54% |
| Earnings Yield | 3.28% |
| FCF Yield | 5.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Novartis AG is 123.79, which is -6.98% lower than the current price. The consensus rating is "Hold".
| Price Target | 123.79 |
| Price Target Difference | -6.98% |
| Analyst Consensus | Hold |
| Analyst Count | 23 |
| Revenue Growth Forecast (3Y) | 4.79% |
| EPS Growth Forecast (3Y) | 6.72% |
Stock Splits
The last stock split was on May 7, 2001. It was a forward split with a ratio of 40.
| Last Split Date | May 7, 2001 |
| Split Type | Forward |
| Split Ratio | 40 |
Scores
Novartis AG has an Altman Z-Score of 3.56 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.56 |
| Piotroski F-Score | 5 |